Mylan Inc arm gets US OK for Tolterodine tartrate tablets

By Admin
Mylan Inc said its arm Mylan Pharmaceuticals Inc has secured final approval from the U.S. Food and Drug Administration for its abbreviated new drug app...

Mylan Inc said its arm Mylan Pharmaceuticals Inc has secured final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Tolterodine tartrate tablets of 1 mg and 2 mg respectively.

This product is the generic version of Pharmacia and Upjohn’s Detrol® Tablets.  It is indicated for treating overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Tolterodine tartrate tablets had U.S. sales of approximately $61.5 million for 12 months ending September 30, 2012 as per IMS Health.

Thirty six of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales for 12 months ending June 30, 2012.

Mylan is a global pharmaceutical company that offers portfolio of more than 1,100 generic pharmaceutical and several brand medications. It also offers a wide range of antiretroviral therapies, on which about one-third of HIV/AIDS patients in developing countries depend. It also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 150 countries and territories.

The company has a workforce of over 18,000 people and is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world.

It also operates a fully integrated specialty pharmaceuticals business, Mylan Specialty, which produces innovative medicinal therapies including EpiPen® auto-injector. 

Share
Share

Featured Articles

Honeywell comments on post-pandemic air quality challenges

Honeywell’s Sarah James calls for air sensors to ensure good air quality & Stefano D’Agostino explores how technology can help improve indoor air quality

Oracle's generative AI prioritises patient healthcare

Oracle's vision for better healthcare focuses on improving medical professionals quality time with patients, with Oracle Clinical Digital Assistant

2San's new app provides vital diagnostic product insights

2San’s leap forward in self diagnostics will bring ‘Better Care, Better Life’ to all, in a new step for 2San’s post-COVID-19 healthcare technology

Cylera’s Richard Staynings on healthcare cybersecurity

Technology & AI

Amazon Prime & One Medical to revolutionise healthcare

Digital Healthcare

Creating robust pharma supply chains with delivery devices

Medical Devices & Pharma